See more : Eslead Corporation (8877.T) Income Statement Analysis – Financial Results
Complete financial analysis of Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heilongjiang ZBD Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tyro Payments Limited (TYR.AX) Income Statement Analysis – Financial Results
- TESSCO Technologies Incorporated (TESS) Income Statement Analysis – Financial Results
- Bohai Ferry Group Co., Ltd. (603167.SS) Income Statement Analysis – Financial Results
- abrdn plc (ABDN.L) Income Statement Analysis – Financial Results
- G2 Goldfields Inc. (GTWO.TO) Income Statement Analysis – Financial Results
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
About Heilongjiang ZBD Pharmaceutical Co., Ltd.
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.14B | 4.22B | 4.13B | 3.41B | 3.30B | 2.79B | 3.14B | 2.39B | 2.07B | 1.59B | 1.41B | 1.38B | 1.07B |
| Cost of Revenue | 1.81B | 3.47B | 2.76B | 1.50B | 1.31B | 790.51M | 1.36B | 848.51M | 454.15M | 588.20M | 471.01M | 568.21M | 470.07M |
| Gross Profit | 1.33B | 744.78M | 1.37B | 1.91B | 1.98B | 2.00B | 1.79B | 1.54B | 1.62B | 1.00B | 943.80M | 811.49M | 601.20M |
| Gross Profit Ratio | 42.39% | 17.65% | 33.09% | 56.11% | 60.14% | 71.62% | 56.84% | 64.52% | 78.09% | 63.07% | 66.71% | 58.82% | 56.12% |
| Research & Development | 80.22M | 70.95M | 55.23M | 81.34M | 86.50M | 90.91M | 93.74M | 70.93M | 92.97M | 67.65M | 58.34M | 62.11M | 0.00 |
| General & Administrative | 117.85M | 108.44M | 103.51M | 114.82M | 123.29M | 122.43M | 120.54M | 122.13M | 56.26M | 48.21M | 40.33M | 43.40M | 135.53M |
| Selling & Marketing | 678.66M | 611.88M | 646.73M | 737.93M | 849.49M | 888.63M | 652.89M | 602.60M | 492.53M | 117.24M | 102.74M | 101.47M | 87.77M |
| SG&A | 796.51M | 720.32M | 750.24M | 852.75M | 972.78M | 1.01B | 773.42M | 724.74M | 548.79M | 165.45M | 143.06M | 144.86M | 223.30M |
| Other Expenses | -243.93M | -405.03M | 92.26M | 284.75M | 208.35M | -23.73M | 1.74M | 96.33M | 66.76M | 38.76M | 6.94M | 6.60M | 1.26M |
| Operating Expenses | 819.15M | 386.23M | 897.73M | 1.22B | 1.27B | 1.26B | 1.06B | 1.03B | 871.86M | 436.62M | 363.52M | 331.31M | 233.91M |
| Cost & Expenses | 2.66B | 3.86B | 3.66B | 2.72B | 2.58B | 2.05B | 2.42B | 1.88B | 1.33B | 1.02B | 834.52M | 899.52M | 703.98M |
| Interest Income | 967.41K | 6.33M | 5.37M | 27.76M | 31.95M | 27.82M | 11.75M | 7.95M | 8.87M | 3.71M | 620.71K | 123.18K | -0.33 |
| Interest Expense | 135.41M | 138.68M | 144.79M | 149.61M | 113.69M | 72.98M | 51.12M | 52.53M | 47.79M | 58.43M | 46.64M | 23.53M | 20.10M |
| Depreciation & Amortization | 201.19M | 181.18M | 154.88M | 177.55M | 157.83M | 138.94M | 136.41M | 161.96M | 115.19M | 95.59M | 75.11M | 63.56M | 56.96M |
| EBITDA | 840.86M | 606.16M | 736.64M | 842.75M | 813.62M | 753.36M | 837.59M | 802.72M | 856.71M | 712.51M | 622.72M | 538.71M | 424.26M |
| EBITDA Ratio | 26.75% | 13.23% | 20.57% | 25.89% | 26.41% | 31.01% | 27.44% | 34.82% | 43.25% | 45.14% | 46.90% | 39.89% | 39.88% |
| Operating Income | 473.24M | 297.53M | 712.41M | 727.34M | 732.14M | 574.23M | 647.93M | 491.31M | 668.29M | 513.06M | 494.14M | 446.17M | 344.89M |
| Operating Income Ratio | 15.05% | 7.05% | 17.25% | 21.32% | 22.21% | 20.61% | 20.63% | 20.54% | 32.24% | 32.21% | 34.93% | 32.34% | 32.19% |
| Total Other Income/Expenses | 5.10M | 958.30K | -257.66M | -190.09M | -194.81M | -23.73M | 1.74M | 96.19M | 25.44M | 36.96M | 10.07M | -26.04M | 608.87K |
| Income Before Tax | 478.35M | 298.48M | 454.75M | 537.25M | 537.33M | 550.49M | 649.67M | 587.49M | 693.73M | 550.02M | 500.98M | 451.61M | 345.50M |
| Income Before Tax Ratio | 15.22% | 7.07% | 11.01% | 15.75% | 16.30% | 19.76% | 20.68% | 24.56% | 33.46% | 34.53% | 35.41% | 32.73% | 32.25% |
| Income Tax Expense | 10.76M | 107.60M | 121.99M | 99.75M | 131.48M | 87.09M | 126.47M | 90.83M | 113.96M | 85.97M | 76.16M | 67.00M | 49.43M |
| Net Income | 472.74M | 185.44M | 332.10M | 436.29M | 408.65M | 462.44M | 520.87M | 509.56M | 585.31M | 477.30M | 436.90M | 389.65M | 296.06M |
| Net Income Ratio | 15.04% | 4.39% | 8.04% | 12.79% | 12.40% | 16.60% | 16.58% | 21.31% | 28.23% | 29.96% | 30.88% | 28.24% | 27.64% |
| EPS | 0.50 | 0.20 | 0.38 | 0.51 | 0.48 | 0.54 | 0.61 | 0.60 | 1.45 | 0.66 | 0.61 | 0.54 | 0.41 |
| EPS Diluted | 0.50 | 0.20 | 0.38 | 0.51 | 0.48 | 0.54 | 0.61 | 0.60 | 1.45 | 0.66 | 0.61 | 0.54 | 0.41 |
| Weighted Avg Shares Out | 940.03M | 941.55M | 864.62M | 849.16M | 849.16M | 849.13M | 849.16M | 849.13M | 403.05M | 720.02M | 722.16M | 721.57M | 722.11M |
| Weighted Avg Shares Out (Dil) | 940.03M | 941.55M | 864.62M | 849.16M | 849.16M | 849.13M | 849.16M | 849.13M | 403.05M | 720.02M | 722.16M | 721.57M | 722.11M |
Source: https://incomestatements.info
Category: Stock Reports